Allgenesis Biotherapeutics

Executive Summary

Allgenesis Biotherapeutics is a private Taiwan-based biotechnology company developing novel ophthalmic therapies for retinal and ocular surface diseases. Leveraging its proprietary bispecific Fc-fusion protein, FPR agonist, and tyrosine kinase inhibitor platforms, the company targets diabetic macular edema (DME), dry eye disease, age-related macular degeneration (AMD), and pterygium. Allgenesis’s lead candidate, a bispecific anti-VEGF/disintegrin fusion protein, is in Phase 2 trials for DME, with initial efficacy and safety data expected in the coming quarters. The company employs around 50–200 professionals and operates with a focus on innovative biologics that address high unmet needs in ophthalmology. Given its early-stage pipeline and lack of approved products, Allgenesis represents a speculative investment opportunity with potential upside from upcoming clinical milestones and strategic collaborations.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead bispecific anti-VEGF/disintegrin candidate in diabetic macular edema40% success
• Q4 2026IND filing for FPR agonist in dry eye disease50% success
• TBDPotential licensing or partnership deal for tyrosine kinase inhibitor program in pterygium30% success